Evidence map›Paper›PMID 39362935›Full record

ArticleScientific reports2024

Pravastatin prevents colitis-associated carcinogenesis by reducing CX3CR1

Kensuke Hachiya, Masahiro Masuya, Naoki Kuroda, Misao Yoneda, Komei Nishimura, Takuya Shiotani, Isao Tawara, Naoyuki Katayama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kensuke HachiyaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan.
Masahiro MasuyaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan. mmasuya@med.mie-u.ac.jp.
Naoki KurodaDepartment of Gastroenterology, Saiseikai Matsusaka General Hospital, Matsusaka, 515- 8557, Mie, Japan.
Misao YonedaDepartment of Clinical Nutrition Medical Technology Course, Suzuka University of Medical Science, Suzuka, 510-0293, Mie, Japan.
Komei NishimuraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan.
Takuya ShiotaniDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan.
Isao TawaraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan.
Naoyuki KatayamaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, 514-8507, Mie, Japan.

Funding

Japan Society for the Promotion of Science Grant 19K08442
6 · The paper itself

Abstract

Colorectal cancer (CRC) resulting from chronic inflammation is a crucial issue in patients with inflammatory bowel disease (IBD). Although many reports established that intestinal resident CX3CR1

Indexed as

ColitisCX3C Chemokine Receptor 1PravastatinAnimalsCarcinogenesisColitis-Associated NeoplasmsColonDextran SulfateDisease Models, AnimalHumansMacrophagesMaleMiceMice, Inbred C57BLCX3C Chemokine Receptor 1Cx3cr1 protein, mouseDextran SulfatePravastatinColorectal neoplasmsCX3CR1FibrocytesInflammationInflammatory bowel diseasesMacrophagesStatin

Identifiers

PMID39362935
PMCPMC11449942

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.